<DOC>
	<DOCNO>NCT02017899</DOCNO>
	<brief_summary>This Phase 1 clinical trial aim evaluate safety immunogenicity 3 dose 5 sequentially escalate dosage candidate vaccine Shigella sonnei ( 1790GAHB vaccine ) administer intramuscular route healthy adult ( 18 45 year age enrollment ) . The safety profile 1790GAHB vaccine evaluate comparison placebo ( GAHB-Placebo ) , constitute aluminum hydroxide suspension concentration study vaccine formulation . A total 50 eligible subject assign one five sequential cohort 10 subject . Within cohort , observer-blind fashion , subject randomize receive three vaccination , four week apart , either 1790GAHB vaccine ( five antigen concentration ) GAHB placebo . A Data Safety Monitoring Board place receive summary safety data obtain one week follow-up post-first vaccination lower dose . Based evaluation safety data , Data Safety Monitoring Board make recommendation , whether next cohort vaccinate high antigen concentration . Expected duration study individual subject 9 month . Each subject followed-up 6 month 3rd vaccination .</brief_summary>
	<brief_title>A Phase 1 , Dose Escalation Study , Evaluate New Shigella Sonnei Vaccine Healthy Adults .</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females age ≥18 year ≤45 year . 2 . Individuals , nature study explain , prior protocol specific procedure perform , give write consent accord local regulatory requirement . 3 . Individuals good health determine outcome medical history , physical examination , hematological / hematochemical blood test ( include presence high antibody titer S. sonnei agglutination test ) , urinalysis clinical judgment investigator . 4 . If woman childbearing potential , negative pregnancy test prior study vaccination willingness use acceptable birth control measure entire study duration . 5 . Individuals affiliate social security regimen . 1 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 2 . Individuals progressive severe neurological disorder , seizure disorder GuillainBarré syndrome . 3 . Individuals able understand follow require study procedure whole period study . 4 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . 5 . Individuals human leukocyte antigen ( HLA ) B27 positive and/or history reactive arthritis . 6 . Individuals know suspected HIV infection HIV related disease , history autoimmune disorder know suspected impairment /alteration immune system , immunosuppressive therapy include use systemic corticosteroid chronic use inhale highpotency corticosteroid ( i.e . prednisone , equivalent ≥10 mg/day ) within previous 28 day , chemotherapy treatment within past 168 day . 7 . Individuals know bleed diathesis , condition may associate prolonged bleeding time . 8 . Individuals serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 9 . Individuals malignancy lymphoproliferative disorder . 10 . Individuals history allergy vaccine component . 11 . Individuals participate clinical trial another investigational product 28 day prior first study visit intent participate another clinical study time conduct study . 12 . Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine within entire study duration except influenza vaccination , allow within period include 28 day 1st vaccination 28 day 3rd vaccination . 13 . Individuals receive blood , blood product , and/or plasma derivative include parenteral immunoglobulin preparation past 12 week . 14 . Individuals part study personnel close family member personnel conduct study employee clinical trial site institution . 15 . Individuals body temperature &gt; 38.0 degree Celsius within 3 day intend study vaccination . 16 . Individuals Body Mass Index ( BMI ) &gt; 30 kg/m2 17 . Individuals history substance alcohol abuse within past 2 year . 18 . Women pregnant breastfeeding , childbearing age use plan use acceptable birth control measure , duration study . 19 . Females history stillbirth , neonatal loss , previous infant anomaly . 20 . Individuals previously laboratory confirm suspected disease cause S. sonnei . 21 . Individuals household contact with/and intimate exposure individual laboratory confirm S. sonnei . 22 . Any condition , , opinion investigator may pose increase unreasonable safety risk subject participate present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>prevention</keyword>
	<keyword>Shigella sonnei</keyword>
</DOC>